Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
•Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer.•A clinically significant dose of olaprib is able to penetrate the leptomeninges.•Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to olaparib.
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Elsevier
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081421/ |